5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction
- PMID: 20488311
- DOI: 10.1016/j.jacc.2009.12.054
5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction
Abstract
Objectives: The objective of this study was to investigate the impact of no-reflow phenomenon on 5-year mortality among patients with acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI). This impact was also assessed in relation to infarct size.
Background: The impact of no-reflow on long-term mortality in patients with STEMI has been insufficiently studied.
Methods: This study included 1,406 patients with STEMI treated by primary PCI. No-reflow was diagnosed using angiographic criteria. Infarct size was measured with single-photon emission computed tomography imaging 7 to 14 days after the acute event. The primary outcome was 5-year mortality.
Results: The no-reflow phenomenon was diagnosed in 410 patients (29%). Infarct size was 15.0% (6.0% to 29.0%) of the left ventricle in the no-reflow group versus 8.0% (2.0% to 21.0%) of the left ventricle in the reflow group (p < 0.001). There were 132 deaths during follow-up. Of them, 59 deaths occurred among patients with no-reflow and 73 deaths occurred among patients with reflow (Kaplan-Meier estimates of 5-year mortality 18.2% and 9.5%, respectively; odds ratio: 2.02; 95% confidence interval: 1.44 to 2.82; p < 0.001). The Cox proportional hazards model adjusting for infarct size among other variables identified the no-reflow phenomenon as an independent correlate of 5-year mortality (hazard ratio: 1.66; 95% confidence interval: 1.17 to 2.36; p = 0.004).
Conclusions: In patients with STEMI treated by primary PCI, no-reflow phenomenon is a strong predictor of 5-year mortality. No-reflow phenomenon after PCI provides prognostic information that is independent of and beyond that provided by infarct size.
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality.Coron Artery Dis. 2014 Aug;25(5):392-8. doi: 10.1097/MCA.0000000000000108. Coron Artery Dis. 2014. PMID: 24625688
-
Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Cardiol J. 2016;23(1):84-92. doi: 10.5603/CJ.a2015.0070. Epub 2015 Oct 27. Cardiol J. 2016. PMID: 26503078
-
The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.Atherosclerosis. 2013 May;228(1):203-10. doi: 10.1016/j.atherosclerosis.2013.02.017. Epub 2013 Feb 24. Atherosclerosis. 2013. PMID: 23489347
-
Predicting the no-reflow phenomenon following successful percutaneous coronary intervention.Biomark Med. 2010 Jun;4(3):403-20. doi: 10.2217/bmm.10.55. Biomark Med. 2010. PMID: 20550474 Review.
-
The "no reflow" phenomenon following acute myocardial infarction: mechanisms and treatment options.J Cardiol. 2014 Aug;64(2):77-85. doi: 10.1016/j.jjcc.2014.03.008. Epub 2014 May 3. J Cardiol. 2014. PMID: 24799155 Review.
Cited by
-
Human epicardial cell-conditioned medium contains HGF/IgG complexes that phosphorylate RYK and protect against vascular injury.Cardiovasc Res. 2015 Jul 15;107(2):277-86. doi: 10.1093/cvr/cvv168. Epub 2015 May 29. Cardiovasc Res. 2015. PMID: 26025956 Free PMC article.
-
Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury.Front Pharmacol. 2019 Jul 24;10:789. doi: 10.3389/fphar.2019.00789. eCollection 2019. Front Pharmacol. 2019. PMID: 31396081 Free PMC article.
-
LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention.Sci Rep. 2022 Feb 28;12(1):3294. doi: 10.1038/s41598-022-06923-z. Sci Rep. 2022. PMID: 35228564 Free PMC article.
-
The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis.J Interv Cardiol. 2022 Nov 30;2022:5815274. doi: 10.1155/2022/5815274. eCollection 2022. J Interv Cardiol. 2022. PMID: 36531287 Free PMC article.
-
Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study.Ann Saudi Med. 2022 Mar-Apr;42(2):75-82. doi: 10.5144/0256-4947.2022.75. Epub 2022 Apr 7. Ann Saudi Med. 2022. PMID: 35380062 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous